# US 10,117,930 B2 · Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,930 B2
- Document ID: US10117930B2
- Status: Granted
- Kind: B2
- Application number: 13/265,252
- Filed: 2010-04-27
- Published: 2012-05-31
- Granted: 2018-11-06
- Earliest claimed: 2009-04-27
- Assignees: Immuron Limited
- Applicants: Yaron Ilan; Gadi Lalazar; Tomer Adar; Meir Mizrahi; Ami Ben-Ya'acov
- Inventors: Yaron Ilan; Gadi Lalazar; Tomer Adar; Meir Mizrahi; Ami Ben-Ya'acov
- Web page: https://patentgrep.com/patent/US10117930B2

## CPC

- A61K 39/39508: {from milk, i.e. lactoglobulins}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/06: Antiasthmatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 16/04: from milk
- C07K 16/1232: Escherichia (G)
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/12: isolated from milk
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to the use of preparations enriched with anti LPS antibodies, such as those derived from mammalian colostrum or avian eggs, and optionally further antibodies against disease-associated antigens, colostrums, milk or milk product component/s and any adjuvants for treating, delaying or preventing the progression of a pathologic disorder such as chronic liver disease, cirrhosis and any complication or disorder associated therewith. The invention further relates to combined compositions comprising a combination of anti-LPS enriched antibody preparations and antibodies recognizing at least one antigen specific for a pathologic disorder and uses thereof in the treatment of immune-related disorders.

## Claims

### Claim 1

A method of improving liver function in a subject with non alcoholic hepatic steatohepatitis (NASH), the method comprising:
selecting a subject who has NASH; and
orally administering to the selected subject a therapeutically effective dose of an anti-LPS enriched immunoglobulin preparation derived from colostrum, thereby improving liver function in the subject with NASH.

### Claim 2 (depends on 1)

The method of claim 1, comprising determining a level of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in the subject, and selecting a subject who has impaired liver function based on the level of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in the subject.

### Claim 3 (depends on 1)

The method of claim 1, further comprising determining a level of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in the subject, wherein a decrease in levels of AST or ALT indicates an improvement in liver function.

### Claim 4 (depends on 1)

The method of claim 1, wherein the colostrum is bovine colostrum.

### Claim 5 (depends on 1)

The method of claim 1, wherein the colostrum is freeze-dried colostrum.

### Claim 6 (depends on 5)

The method of claim 5, wherein the freeze-dried colostrum is in a tablet.